Grant: Alliance Grants
University of Toronto
$97,140.00
A digital microfluidic live-cell imaging system to empower automated, multiplexed protein kinase activity reporter assays
EF 2024-25
Résumé
Precise disease modelling is imperative to developing treatments that mitigate disease without unintended consequences. This is especially true in cancer treatments, where treatment efficacy can vary greatly from patient-to-patient depending on the cell type that cancer cells originate from. In this NSERC Alliance proposal, Sartorius AG, Virica Biotech, and the Wheeler research group at the University of Toronto propose to work together to develop an automated, multiplexed platform based around a particularly powerful tool in the cancer research toolbox, the fluorescence-based kinase activity reporters (KAR). Fluorescent KARs have been employed for over twenty years in cancer research and have distinct advantages over other methods to study signalling events in cancer cells. Importantly, KARs are used to measure the functional activity of cancer-related proteins in live cells, rather than inferred activity based on protein or RNA abundance. Despite their valuable contributions to basic research, KARs are not traditionally used in automated drug screening, since they typically require manual addition of drugs-of-interest to cells during a live cell imaging time-course. Here, we propose to develop an automated, multiplexed live-cell imaging platform relying on DMF and KARs. The project will culminate with the application of the microfluidic platform to a pilot, multiplexed screen to test kinase activities across a library of cell lines, to capture cell-specific responses to each candidate in parallel. This project will provide cutting-edge training to Canadian trainees, will contribute to the development and translation of new "invented in Canada" technologies, and will provide a unique opportunity for a Canadian industry partner (Virica) to benefit from collaboration and co-development with a market-leading international partner (Sartorius).
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
597396-2024
Name nom
Wheeler, Aaron AR
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
97140
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
A digital microfluidic live-cell imaging system to empower automated, multiplexed protein kinase activity reporter assays
Keywords
bioreactor; cell culture; live cell imaging; microfluidics
Application summary
Precise disease modelling is imperative to developing treatments that mitigate disease without unintended consequences. This is especially true in cancer treatments, where treatment efficacy can vary greatly from patient-to-patient depending on the cell type that cancer cells originate from. In this NSERC Alliance proposal, Sartorius AG, Virica Biotech, and the Wheeler research group at the University of Toronto propose to work together to develop an automated, multiplexed platform based around a particularly powerful tool in the cancer research toolbox, the fluorescence-based kinase activity reporters (KAR). Fluorescent KARs have been employed for over twenty years in cancer research and have distinct advantages over other methods to study signalling events in cancer cells. Importantly, KARs are used to measure the functional activity of cancer-related proteins in live cells, rather than inferred activity based on protein or RNA abundance. Despite their valuable contributions to basic research, KARs are not traditionally used in automated drug screening, since they typically require manual addition of drugs-of-interest to cells during a live cell imaging time-course. Here, we propose to develop an automated, multiplexed live-cell imaging platform relying on DMF and KARs. The project will culminate with the application of the microfluidic platform to a pilot, multiplexed screen to test kinase activities across a library of cell lines, to capture cell-specific responses to each candidate in parallel. This project will provide cutting-edge training to Canadian trainees, will contribute to the development and translation of new "invented in Canada" technologies, and will provide a unique opportunity for a Canadian industry partner (Virica) to benefit from collaboration and co-development with a market-leading international partner (Sartorius).